Skip to search formSkip to main contentSkip to account menu

AZD6738

Known as: ATR Kinase Inhibitor AZD6738, AZD-6738 
An orally available morpholino-pyrimidine-based inhibitor of ataxia telangiectasia and rad3 related (ATR) kinase, with potential antineoplastic… 
National Institutes of Health

Related topics

Related topics

3 relations
NCIt Antineoplastic Agent Terminology

Broader (2)

PyrimidinesSulfoxides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Results from a phase I, open-label study of ceralasertib (AZD6738), a novel DNA damage repair agent, in combination with weekly paclitaxel in refractory cancer (NCT02630199).
3503Background: Ataxia Telangiectasia and Rad3 Related (ATR) is an apical kinase with a critical role in the DNA-damage response… 
2019
2019
ATR kinase inhibition sensitizes quiescent human cells to the lethal effects of cisplatin but increases mutagenesis.
2019
2019
Simultaneous cotargeting of ATR and RNA Polymerase I transcription demonstrates synergistic antileukemic effects on acute myeloid leukemia
Dear Editor, Continued development of novel therapeutic agents is critical to improve the survival of patients with acute myeloid… 
2018
2018
VIOLETTE: A randomized phase II study to assess DNA damage response inhibitors in combination with olaparib (Ola) vs Ola monotherapy in patients (pts) with metastatic, triple-negative breast cancer…
TPS1116Background: Invasive BC is diagnosed in > 255,000 pts in the US annually, and TNBC comprises ≈15% of cases. Alterations in… 
2018
2018
Abstract LB-263: Preclinical efficacy of the ATR inhibitor AZD6738 in combination with the BTK inhibitor acalabrutinib in ABC-DLBCL models
Bruton tyrosine kinase (BTK) is an essential kinase in the B-cell receptor (BCR) signalling pathway. Acalabrutinib is a potent… 
2017
2017
Abstract CT084: A Phase I dose-escalation study of ATR inhibitor monotherapy with AZD6738 in advanced solid tumors (PATRIOT Part A)
Many cancers have high levels of replication stress and a poorly functional G1/S DNA damage checkpoint. This may render them more… 
2016
2016
Phase I modular study of AZD6738, a novel oral, potent and selective ataxia telangiectasia Rad3-related (ATR) inhibitor in combination (combo) with carboplatin, olaparib or durvalumab in patients…
Review
2015
Review
2015
O6.3ATR inhibitor AZD6738.
ABSTRACT AZD6738 is a potent and selective orally bio-available inhibitor of ataxia telangiectasia and rad3 related (ATR),a key… 
2015
2015
Using gamma-H2AX and H2AX quantitative ELISA for monitoring DNA damage induced by chemotherapeutic agents and irradiation exposure.
2559 Background: Gamma-H2AX (γH2AX) is a biomarker for DNA double-strand breaks and programmed cell death, but variable relative… 
2014
2014
Abstract 5485: Induction of proliferation sensitizes chronic lymphocytic leukemia cells to apoptosis mediated by the ATR inhibitor AZD6738
ATR (Ataxia Telangiectasia and RAD3-related) is a PI3K-related kinase involved in repair of DNA damage incurred through the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)